Cadrenal TherapeuticsCVKD
13F holders, Q1 2026 (March 31)17holders −1
3new positions
5sold out
$5.05avg. 13F price*
At the end of Q1 2026, 17 institutions reported holding Cadrenal Therapeutics Inc. (CVKD) in their 13F filings, down 1 from Q4 2025. 3 opened new positions and 5 sold out. The largest holders were Vanguard Capital Management LLC ($231K), Geode Capital Management, LLC ($111K) and Vanguard Fiduciary Trust Co. ($43K).
- Company
- Cadrenal Therapeutics Inc.
- CUSIP
- 127636207
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $9K |
| Exits | 5 | $260K |
All 13F filers, Q4 2025 → Q1 2026: 10,765 shares bought and 40,913 shares sold, net −30,148 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 17 holders
| Vanguard Capital Management LLC | 0.00% | — | 45,201 | $231K |
| Geode Capital Management, LLC | 0.00% | Add +48.9% | 21,626 | $111K |
| Vanguard Fiduciary Trust Co. | 0.00% | — | 8,311 | $43K |
| JPMorgan Chase & Co. | 0.00% | No change | 7,500 | $32K |
| BlackRock, Inc. | 0.00% | Add +56.0% | 5,496 | $28K |
| Cygnus Capital Advisors, LLC | 0.01% | New | 1,492 | $8K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -26.1% | 393 | $2K |
| Osaic Holdings, Inc. | 0.00% | Reduce -40.0% | 300 | $2K |
| Destiny Wealth Partners, LLC | 0.00% | New | 200 | $1K |
| Rockefeller Capital Management L.P. | 0.00% | Reduce -50.0% | 150 | $768 |
| Morgan Stanley | 0.00% | Reduce -90.7% | 100 | $512 |
| Wells Fargo & Company | 0.00% | No change | 99 | $507 |
| Archer Investment Corp | 0.00% | No change | 35 | $179 |
| IFP Advisors, Inc | 0.00% | No change | 30 | $154 |
| UBS Group AG | 0.00% | Reduce -99.7% | 3 | $15 |
| Citigroup Inc. | 0.00% | New | 1 | $5 |
| Curio Wealth, LLC | 0.00% | No change | 1 | $5 |
"% of holder's portfolio" is CVKD's weight in each manager's 13F, not the share of Cadrenal Therapeutics Inc. the manager owns.